Top Ten Cardiovascular Medical Devices Companies – the Share of Top Institutional InvestorsCurators: Adam Sonnenberg, BSc and Aviva Lev-Ari, PhD, RN Top Ten Cardiovascular Medical Devices Industry Leaders |
| Medtronic
http://investors.morningstar.com/ownership/shareholders-major.html?t=MDT |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Total Stock Mkt Idx 2.48% |
| Vanguard Windsor™ II Inv 1.86% |
| SPDR® S&P 500 ETF 1.59% |
| Vanguard 500 Index Inv 1.59% |
| Vanguard Institutional Index 1.49% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Abbott Labs |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Total Stock Mkt Idx 1.72% |
| Vanguard 500 Index Inv 1.10% |
| SPDR® S&P 500 ETF 1.08% |
| Vanguard Institutional Index I 1.04% |
| Vanguard Dividend Appreciation ETF .73% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Baxter http://investors.morningstar.com/ownership/shareholders-major.html?t=BAX |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Total Stock Mkt Idx 1.72% |
| Vanguard 500 Index Inv 1.10% |
| SPDR® S&P 500 ETF 1.04% |
| Vanguard Institutional Index I 1.04% |
| AllianzGI NFJ Dividend Value Instl .98% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Johnson&Johnson |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Total Stock Mkt Idx 1.72% |
| Vanguard 500 Index Inv 1.10% |
| SPDR® S&P 500 ETF 1.04% |
| Vanguard Institutional Index I 1.04% |
| Fidelity® Contrafund® .68% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Engologix |
| Institutional Investors in Cardiovascular Medical Devices |
| Janus Triton D 5.33% |
| ClearBridge Small Cap Growth A 2.80% |
| Janus Venture D 2.54% |
| Meridian Growth Legacy 2.49% |
| Janus Global Life Sciences D 2.19% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Boston Scientific
http://investors.morningstar.com/ownership/shareholders-major.html?t=BSX®ion=USA |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Health Care Inv 4.49% |
| Vanguard PRIMECAP Inv 2.14% |
| VA CollegeAmerica Grth Fund of Amer 529F 1.77% |
| Vanguard Mid Cap Index I 1.82% |
| Vanguard Total Stock Mkt Idx 1.72% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| St Jude Medical |
| Institutional Investors in Cardiovascular Medical Devices |
| VA CollegeAmerica Grth Fund of Amer 529F 3.47% |
| VA CollegeAmerica Cap World G/I 529E 3.02% |
| VA CollegeAmerica Amcap 529F 2.37% |
| Vanguard Health Care Inv 1.89% |
| VA CollegeAmerica Invmt Co of Amer 529E 1.76% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Becton Dickson |
| Institutional Investors in Cardiovascular Medical Devices |
| Vanguard Total Stock Mkt Idx 1.71% |
| Franklin Rising Dividends Fund A 1.64% |
| Vanguard Health Care Inv 1.37% |
| Jensen Quality Growth J 1.31% |
| T. Rowe Price Capital Appreciation 1.13% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| EdwardsLS |
| Institutional Investors in Cardiovascular Medical Devices |
| VA CollegeAmerica Grth Fund of Amer 529F 4.79% |
| Vanguard Health Care Inv 3.18% |
| VA CollegeAmerica Amcap 529F 3.01% |
| Vanguard Mid Cap Index I 1.82% |
| Vanguard Total Stock Mkt Idx 1.72% |
| Top Ten Cardiovascular Medical Devices Industry Leaders |
| Bard (C.R.) Inchttp://investors.morningstar.com/ownership/shareholders-major.html?t=BCR®ion=usa&culture=en-US&ownerCountry=USA |
| Institutional Investors in Cardiovascular Medical Devices |
| AMG Yacktman Service 2.80% |
| AMG Yacktman Focused Service 2.15% |
| Vanguard Mid Cap Index I 1.82% |
| Vanguard Total Stock Mkt Idx 1.72% |
| Vanguard Health Care Inv 1.22% |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.